Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

被引：0

作者：

Martin Fenner

Christoph Oing

Annette Dieing

Thomas Gauler

Karin Oechsle

Anja Lorch

Marcus Hentrich

Hans-Georg Kopp

Carsten Bokemeyer

Friedemann Honecker

机构：

[1] Hannover Medical School,Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation

[2] University Medical Center Hamburg-Eppendorf,Department of Oncology, Hematology and Bone Marrow Transplantation and Section of Pneumology

[3] Vivantes Hospital am Urban,Department of Hematology and Oncology

[4] Heinrich Heine University Medical Center Essen,Department of Radiotherapy and Radiation Oncology

[5] University Medical Center Duesseldorf,Genitourinary Medical Oncology, Department of Urology

[6] Red Cross Hospital Munich,Department of Internal Medicine III, Hematology and Oncology

[7] University Medical Center Tuebingen,Department of Oncology, Hematology, Clinical Immunology, Rheumatology and Pulmonology

[8] Robert-Bosch-Centrum für Tumorerkrankungen,Department of Molecular Oncology and Pneumological Oncology

[9] Robert-Bosch Hospital,undefined

[10] ZeTuP Tumor and Breast Center,undefined

[11] DataCite,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷

关键词：

Germ cell cancer; Testicular cancer; mTOR; Everolimus; Refractory; Cisplatin resistance;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：717 / 723

页数：6

共 50 条

[41] Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
Suzuki, Kenshi
Sunami, Kazutaka
Matsumoto, Morio
Maki, Akio
Shimada, Fumika
Suzuki, Kazuyuki
Shimizu, Kazuyuki
ACTA HAEMATOLOGICA, 2021, 144 (03) : 264 - 274
[42] Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Xu, Jianming
Li, Jie
Bai, Chunmei
Xu, Nong
Zhou, Zhiwei
Li, Zhiping
Zhou, Caicun
Jia, Ru
Lu, Ming
Cheng, Yuejuan
Mao, Chenyu
Wang, Wei
Cheng, Ke
Su, Chunxia
Hua, Ye
Qi, Chuan
Li, Jing
Wang, Wei
Li, Ke
Sun, Qiaoling
Ren, Yongxin
Su, Weiguo
CLINICAL CANCER RESEARCH, 2019, 25 (12) : 3486 - 3494
[43] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
Song, Zhengbo
Lou, Guangyuan
Wang, Yina
Yang, Zhiping
Wang, Wenxian
Ji, Yongling
Chen, Shiqing
Xu, Chunwei
Hu, Xiao
Zhang, Yiping
BMC MEDICINE, 2022, 20 (01)
[44] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
Zhengbo Song
Guangyuan Lou
Yina Wang
Zhiping Yang
Wenxian Wang
Yongling Ji
Shiqing Chen
Chunwei Xu
Xiao Hu
Yiping Zhang
BMC Medicine, 20
[45] Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial
Gao, Yan
Huang, Yunhong
Zhang, Qingyuan
Yang, Haiyan
Li, Yufu
Li, Yan
Zhou, Min
Yang, Runxiang
Xu, Bing
Liu, Lihong
Yang, Yu
Peng, Zhigang
Yu, Ding
Zhou, Hui
Zhang, Rongyan
Zhang, Huilai
Qi, Junyuan
Xi, Yaming
Xing, Xiaojing
Wang, Zhao
Jing, Hongmei
Shuang, Yuerong
Zhang, Xiaohong
Ma, Liping
Jin, Hongyan
Lin, Li'e
Li, Chunlei
Xue, Jianfei
Liu, Yanping
Yuan, Jing
Huang, Huiqiang
CANCER, 2025, 131 (01)
[46] Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study
Jin, Jie
Zhang, Yi
Zhang, Qike
Liu, Qingchi
Zhou, Hu
Gao, Sujun
Wang, Wei
Dang, Huibing
Chen, Yuqing
Wang, Jishi
Zhao, Peng
Yang, Haiping
Ma, Liangming
Zhao, Qingwei
Suo, Shanshan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Huang, Huiqiang
Zhu, Jun
Yao, Ming
Kim, Tae Min
Yoon, Dok Hyun
Cho, Seok-Goo
Eom, Hyeon Seok
Lim, Soon Thye
Yeh, Su-peng
Song, Yuqin
Kwong, Yok Lam
Kim, Jin Seok
Jin, Jie
Shi, Yuankai
Kim, HyeJin
Qing, Min
Zhou, Tianyuan
Gao, Grace
Dong, Zongqi
Qi, Ming
Kim, Won Seog
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[48] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Huiqiang Huang
Jun Zhu
Ming Yao
Tae Min Kim
Dok Hyun Yoon
Seok-Goo Cho
Hyeon Seok Eom
Soon Thye Lim
Su-peng Yeh
Yuqin Song
Yok Lam Kwong
Jin Seok Kim
Jie Jin
Yuankai Shi
HyeJin Kim
Min Qing
Tianyuan Zhou
Grace Gao
Zongqi Dong
Ming Qi
Won Seog Kim
Journal of Hematology & Oncology, 14
[49] Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
Schwartzberg, Lee
Hermann, Robert
Flinn, Ian
Flora, Douglas
Hsi, Eric D.
Hamid, Oday
Shi, Peipei
Lin, Boris K.
Myrand, Scott P.
Nguyen, Tuan S.
Dreyling, Martin
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 91 - 97
[50] Blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: An open-label, single-arm, multicenter confirmatory phase 2 study
Topp, M. S.
Goekbuget, N.
Stein, A. S.
Bargou, R. C.
Dombret, H.
Fielding, A. K.
Ribera, J. M.
Foa, R.
Zugmaier, G.
Jia, C.
Maniar, T.
Huber, B.
Nagorsen, D.
Kantarjian, H. M.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 181 - 181

← 1 2 3 4 5 →